🚀 VC round data is live in beta, check it out!
Dyadic Valuation Multiples
Discover revenue and EBITDA valuation multiples for Dyadic and similar public comparables like Eden Research, Bioceres, Desert Control, Plant Advanced Technologies and more.
Dyadic Overview
About Dyadic
Dyadic International Inc is a worldwide biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
Founded
2002
HQ
Employees
6
Website
Financials (LTM)
EV
$30M
Dyadic Financials
Dyadic reported last 12-month revenue of $4M.
In the same LTM period, Dyadic generated $2M in gross profit and had net loss of ($6M).
Revenue (LTM)
Dyadic P&L
In the most recent fiscal year, Dyadic reported revenue of $3M and EBITDA of ($7M).
Dyadic expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $4M | XXX | $3M | XXX | XXX | XXX |
| Gross Profit | $2M | XXX | ($1M) | XXX | XXX | XXX |
| Gross Margin | 39% | XXX | (35%) | XXX | XXX | XXX |
| EBITDA | — | XXX | ($7M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (224%) | XXX | XXX | XXX |
| EBIT Margin | (145%) | XXX | (231%) | XXX | XXX | XXX |
| Net Profit | ($6M) | XXX | ($7M) | XXX | XXX | XXX |
| Net Margin | (147%) | XXX | (238%) | XXX | XXX | XXX |
| Net Debt | — | — | $404K | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Dyadic Stock Performance
Dyadic has current market cap of $32M, and enterprise value of $30M.
Market Cap Evolution
Dyadic's stock price is $0.88.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $30M | $32M | -0.1% | XXX | XXX | XXX | $-0.20 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialDyadic Valuation Multiples
Dyadic trades at 7.1x EV/Revenue multiple, and (4.3x) EV/EBITDA.
EV / Revenue (LTM)
Dyadic Financial Valuation Multiples
As of April 22, 2026, Dyadic has market cap of $32M and EV of $30M.
Equity research analysts estimate Dyadic's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Dyadic has a P/E ratio of (5.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $32M | XXX | $32M | XXX | XXX | XXX |
| EV (current) | $30M | XXX | $30M | XXX | XXX | XXX |
| EV/Revenue | 7.1x | XXX | 9.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (4.3x) | XXX | XXX | XXX |
| EV/EBIT | (4.9x) | XXX | (4.2x) | XXX | XXX | XXX |
| EV/Gross Profit | 18.4x | XXX | (27.4x) | XXX | XXX | XXX |
| P/E | (5.2x) | XXX | (4.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (5.2x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Dyadic Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Dyadic Margins & Growth Rates
Dyadic's revenue in the last 12 month grew by 109%.
Dyadic's revenue per employee in the last FY averaged $0.5M, while opex per employee averaged $1.0M for the same period.
Dyadic Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 109% | XXX | 118% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (224%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 28% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.0M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 131% | XXX | 187% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 52% | XXX | 70% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 196% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Dyadic Public Comps
See public comps and valuation multiples for other Bioindustrials comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Dyadic | XXX | XXX | XXX | XXX | XXX | XXX |
| Eden Research | XXX | XXX | XXX | XXX | XXX | XXX |
| Bioceres | XXX | XXX | XXX | XXX | XXX | XXX |
| Desert Control | XXX | XXX | XXX | XXX | XXX | XXX |
| Plant Advanced Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| Nutriplant | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dyadic M&A Activity
Dyadic acquired XXX companies to date.
Last acquisition by Dyadic was on XXXXXXXX, XXXXX. Dyadic acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Dyadic
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialDyadic Investment Activity
Dyadic invested in XXX companies to date.
Dyadic made its latest investment on XXXXXXXX, XXXXX. Dyadic invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Dyadic
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Dyadic
| When was Dyadic founded? | Dyadic was founded in 2002. |
| Where is Dyadic headquartered? | Dyadic is headquartered in United States. |
| How many employees does Dyadic have? | As of today, Dyadic has over 6 employees. |
| Who is the CEO of Dyadic? | Dyadic's CEO is Mark A. Emalfarb. |
| Is Dyadic publicly listed? | Yes, Dyadic is a public company listed on Nasdaq. |
| What is the stock symbol of Dyadic? | Dyadic trades under DYAI ticker. |
| When did Dyadic go public? | Dyadic went public in 2004. |
| Who are competitors of Dyadic? | Dyadic main competitors are Eden Research, Bioceres, Desert Control, Plant Advanced Technologies. |
| What is the current market cap of Dyadic? | Dyadic's current market cap is $32M. |
| What is the current revenue of Dyadic? | Dyadic's last 12 months revenue is $4M. |
| What is the current revenue growth of Dyadic? | Dyadic revenue growth (NTM/LTM) is 109%. |
| What is the current EV/Revenue multiple of Dyadic? | Current revenue multiple of Dyadic is 7.1x. |
| Is Dyadic profitable? | No, Dyadic is not profitable. |
| What is the current net income of Dyadic? | Dyadic's last 12 months net income is ($6M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.